Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vanda Pharmaceuticals Inc. Director's Dealing 2009

May 27, 2009

33390_dirs_2009-05-27_837679d7-29ce-4add-bf8e-5f442eec236a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vanda Pharmaceuticals Inc. (VNDA)
CIK: 0001347178
Period of Report: 2009-05-22

Reporting Person: Polymeropoulos Mihael Hristos (Director, Chief Executive Officer)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2009-05-22 Employee Stock Option (Right to Buy) $12.55 A 250000 Acquired 2019-05-21 Common Stock (250000) Direct

Footnotes

F1: The option vests each month with respect to 2.0833% of the aggregate option share total.